Lucintel Forecasts The Global Ocular Gene Therapy Market To Grow With A Cagr Of 15.1% From 2025 To 2031

By Author: Lucintel LLC
Total Articles: 7912
Comment this article

According to a market report by Lucintel, the future of the global ocular gene therapy market looks promising with opportunities in the hospitals, diagnostics centers and research institutes markets. The global ocular gene therapy market is expected to grow with a CAGR of 15.1% from 2025 to 2031. The major drivers for this market are the increasing prevalence of ocular diseases and the regulatory approvals & increased investment in R&D.
A more than 150-page report to understand trends, opportunity and forecast in global ocular gene therapy market to 2031 by type (gene replacement technology, gene editing technology, and others), application (hospitals, diagnostics centers, and research institutes), and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel forecasts that, within the type category, gene replacement technology is expected to witness higher growth over the forecast period due to broader application & versatility.
Within the application category, hospital is expected to witness the higher growth due to high prevalence of ocular diseases.
Download sample ...
... by clicking on ocular gene therapy market.
In terms of region, North America is expected to witness the highest growth over the forecast period.
AbbVie, MeriaGTx, Regenxbio, GenSight Biologics, Astellas are the major suppliers in the ocular gene therapy market.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
Encephalitis Vaccine Market
EC Cross Flow Fan Market
Decontamination Kit for Flow Cytometry Market
Carton Flow Rack Market
Brucellosis Vaccine Market